The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1233
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Insulin glulisine (Apidra – Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog)1 and insulin aspart (Novolog).2 All three have a more rapid onset and shorter duration of action than regular human insulin.3 Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.

PHARMACOKINETICS — Endogenous plasma insulin concentrations normally peak less than one hour after meals and return to baseline by 4 hours. In patients with diabetes, subcutaneous injection of regular human insulin 30 minutes before meals, the usual recommendation, results in plasma insulin concentrations that peak in 2-4 hours and remain elevated for 5-10 hours. As a result, blood glucose concentrations may be high immediately ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin
Article code: 1233a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian